AIM: To assess the significance of interleukin (IL)-24 and vascular endothelial growth factor (VEGF) expression in lymph-node-positive rectal cancer. METHODS: Between 1998 and 2005, 90 rectal adenocarcinoma patients with lymph node involvement were enrolled. All patients received radical surgery and postoperative pelvic chemoradiotherapy of 50.4-54.0 Gy. Chemotherapy of 5-fluorouracil and leucovorin or levamisole was given intravenously during the first and last week of radiotherapy, and then monthly for about 6 mo. Expression of IL-24 and VEGF was evaluated by immunohistochemical staining of surgical specimens, and their relations with patient characteristics and survival were analyzed. The median follow-up of surviving patients was 73 mo (range: 52-122 mo). RESULTS: IL-24 expression was found in 81 out of 90 patients; 31 showed weak intensity and 50 showed strong intensity. VEGF expression was found in 64 out of 90 patients. Negative and weak intensities of IL-24 expression were classified as negative expression for analysis. IL-24 expression was significantly reduced in poorly differentiated tumors in comparison with well or moderately differentiated tumors (P = 0.004), N2b to earlier N stages (P = 0.016), and stage IIIc to stage IIIa or IIIb (P = 0.028). The number of involved lymph nodes was also significantly reduced in IL-24-positive patients in comparison with IL-24-negative ones.There was no correlation between VEGF expression and patient characteristics. Expression of IL-24 and VEGF was not correlated with survival, but N stage and stages were significantly correlated with survival. CONCLUSION: IL-24 expression was significantly correlated with histological differentiation, and inversely correlated with the degree of lymph node involvement in stage III rectal cancer.
AIM: To assess the significance of interleukin (IL)-24 and vascular endothelial growth factor (VEGF) expression in lymph-node-positive rectal cancer. METHODS: Between 1998 and 2005, 90 rectal adenocarcinomapatients with lymph node involvement were enrolled. All patients received radical surgery and postoperative pelvic chemoradiotherapy of 50.4-54.0 Gy. Chemotherapy of 5-fluorouracil and leucovorin or levamisole was given intravenously during the first and last week of radiotherapy, and then monthly for about 6 mo. Expression of IL-24 and VEGF was evaluated by immunohistochemical staining of surgical specimens, and their relations with patient characteristics and survival were analyzed. The median follow-up of surviving patients was 73 mo (range: 52-122 mo). RESULTS:IL-24 expression was found in 81 out of 90 patients; 31 showed weak intensity and 50 showed strong intensity. VEGF expression was found in 64 out of 90 patients. Negative and weak intensities of IL-24 expression were classified as negative expression for analysis. IL-24 expression was significantly reduced in poorly differentiated tumors in comparison with well or moderately differentiated tumors (P = 0.004), N2b to earlier N stages (P = 0.016), and stage IIIc to stage IIIa or IIIb (P = 0.028). The number of involved lymph nodes was also significantly reduced in IL-24-positive patients in comparison with IL-24-negative ones.There was no correlation between VEGF expression and patient characteristics. Expression of IL-24 and VEGF was not correlated with survival, but N stage and stages were significantly correlated with survival. CONCLUSION:IL-24 expression was significantly correlated with histological differentiation, and inversely correlated with the degree of lymph node involvement in stage III rectal cancer.
Authors: Y Toiyama; Y Inoue; S Saigusa; Y Okugawa; T Yokoe; K Tanaka; C Miki; M Kusunoki Journal: Clin Oncol (R Coll Radiol) Date: 2010-02-01 Impact factor: 4.126
Authors: Adly Yacoub; Clint Mitchell; Andrea Lister; Irina V Lebedeva; Devanand Sarkar; Zao-Zhong Su; Carter Sigmon; Robert McKinstry; Viswanathan Ramakrishnan; Liang Qiao; William C Broaddus; Rahul V Gopalkrishnan; Steven Grant; Paul B Fisher; Paul Dent Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Irina V Lebedeva; Devanand Sarkar; Zao-Zhong Su; Shinichi Kitada; Paul Dent; C A Stein; John C Reed; Paul B Fisher Journal: Oncogene Date: 2003-11-27 Impact factor: 9.867
Authors: S Cascinu; F Graziano; V Catalano; M P Staccioli; M C Rossi; A M Baldelli; S Barni; A Brenna; S Secondino; P Muretto; G Catalano Journal: Br J Cancer Date: 2002-03-04 Impact factor: 7.640
Authors: Hiroshi Mitsui; Mayte Suárez-Fariñas; Nicholas Gulati; Kejal R Shah; Maria V Cannizzaro; Israel Coats; Diane Felsen; James G Krueger; John A Carucci Journal: J Invest Dermatol Date: 2013-11-22 Impact factor: 8.551